Preclinical studies suggest that a diversity of nicotinic acetylcholine receptors (nAChRs) with different sensitivities to nicotine may contribute to tobacco addiction. Using rodent intravenous nicotine self-administration as a preclinical model with good predictive validity for therapeutic efficacy for tobacco cessation, investigators have identified heteromeric ␣6␤2 * and homomeric ␣7 nAChRs as promising novel therapeutic targets to promote smoking abstinence ( * denotes possible assembly with other subunits). The data suggest that diverse strategies that target these subclasses of nAChRs, namely inhibition of ␣6␤2 * nAChRs and stimulation of ␣7 nAChRs, will support tobacco cessation. ␣6␤2 * nAChRs, members of the high-affinity family of ␤2 * nAChRs, function similarly to ␣4␤2 * nAChRs, the primary target of the FDA-approved drug varenicline, but have a much more selective neuroanatomical pattern of expression in catecholaminergic nuclei. Although activation of ␤2 * nAChRs facilitates nicotine self-administration, stimulation of ␣7 nAChRs appears to negatively modulate both nicotine reinforcement and ␤2 * nAChR function in the mesolimbic dopamine system. Although challenges and caveats must be considered in the development of therapeutics that target these nAChR subpopulations, an accumulation of data suggests that ␣7 nAChR agonists, partial agonists, or positive allosteric modulators and ␣6␤2 * nAChR antagonists, partial agonists, or negative allosteric modulators may prove to be effective therapeutics for tobacco cessation.
Introduction
Reductions in tobacco smoking have reached a plateau in developed countries where a majority of smokers report wanting to quit. 1 Many of these individuals are nonresponsive to currently available therapeutics for tobacco cessation. When nicotine replacement is delivered via routes of administration considered safer than smoking, it greatly increases abstinence in comparison to smokers who use no therapy, but still only assists a small minority of smokers in quitting. 2 Nicotine in tobacco exerts its psychoactive effects at a diversity of nicotinic acetylcholine receptors (nAChRs) where it both stimulates these receptors and inactivates them via desensitization. Although most preclinical studies suggest that activation of ␤2 subunit-containing nicotinic receptors (␤2 * nAChRs;
* denotes possible assembly with other subunits) is required for nicotine reinforcement and reward, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] it remains unclear from a therapeutic perspective whether activation or inhibition of diverse nicotinic receptor subtypes may best support tobacco cessation. 13 Bupropion, an FDA-approved smoking cessation drug that acts as a dopamine (DA) and norepinephrine (NE) transporter blocker, also has antagonist properties at nAChRs. 14 Mixed agonist/antagonist strategies have been proposed to support tobacco cessation. [15] [16] [17] Considerable increases in therapeutic efficacy are observed with varenicline and the natural derivative of the golden rain plant, cytosine, 18 which, as partial agonists of ␣4␤2 * nAChRs, have mixed agonist and antagonist properties. Given the diversity of nAChRs and their functions, it is possible that the effectiveness of varenicline may also be attributed in part to its selective nAChR targeting of the ␤2 * nAChRs, including ␣4␤2 * nAChRs and ␣6␤2 * nAChRs. Although with lower affinity, varenicline is also a full agonist at ␣7 nAChRs and ␣3␤4 * nAChRs, 19, 20 which preclinical data suggest may make important contributions to the tobacco dependence phenotype. [21] [22] [23] [24] [25] 
␣4␤2
* nAChRs have been well studied for their role in promoting a nicotine addiction phenotype. 4, [7] [8] [9] [10] [11] 26 On the basis of data from rodent intravenous self-administration of nicotine (a preclinical model with good predictive validity for therapeutics for smoking cessation), this review will focus on two novel nAChR targets for tobacco cessation: the ␣7 homomeric nAChRs and the highsensitivity heteromeric nAChRs containing ␣6 and ␤2 subunits (␣6␤2 * nAChRs). The reader is referred to other published articles 21, 27, 28 for a more comprehensive review of nAChR localization and contributions to tobacco addiction. When justified, this review will specify a more complete representation of subunits, but otherwise will more conservatively use the nomenclature with an asterisk ( * ) to indicate that the precise subunit composition has yet to be determined.
This review will also provide the reader with an overview of nAChR composition and function, highlighting differences between the ␣7 and ␣6␤2 * nAChRs. Not only do these diverse receptor subtypes respond differently to nicotinic agonists, such as acetylcholine (ACh) and nicotine, but our review of the literature shows that the ␣7 and ␣6␤2 * nAChR subtypes also differentially regulate nicotine addiction behavior. Of importance from a therapeutic perspective, activation of ␣6␤2 * nAChRs, such as ␣4␤2 * nAChRs, supports the reinforcing efficacy of systemically administered nicotine; 3, 5, 9, 10, 29, 30 in contrast, inhibition of ␣7 nAChRs facilitates rodent motivation to self-administer nicotine. 22 Thus, with nicotine self-administration as a behavioral endpoint, it appears that ␣7 nAChRs work in opposition to ␤2 * nAChRs. These preclinical data suggest that novel therapeutic strategies for smoking cessation include inhibition of ␣6␤2 * nAChRs and activation of ␣7 nAChRs. Due to their unique neuroanatomical expression profiles, therapeutics targeting ␣7 nAChRs and ␣6␤2 * nAChRs may benefit different populations of smokers than those who have quit with existing therapies. The rather selective expression of ␣6␤2 * nAChRs in catecholaminergic nuclei, including the mesolimbic DA pathway, 31, 32 suggests that targeted treatment of this nAChR subtype could benefit smokers while having reduced potential for side effects (but for considerations, see the section below on pharmacological tools). The expression of ␣7 nAChRs overlaps with that of ␣6␤2 * and ␣4␤2 * nAChRs within the mesolimbic circuitry but is enriched in areas complementary to ␣4␤2 * nAChRs that support cognition and arousal. 33 However, it should be noted that while overlapping at the tissue level, the expression of ␣7 and ␣6␤2 * nAChR are distinctly different at the cellular and subcellular levels in these tissues. 34 This review includes a section focusing on drug development strategies and caveats for pharmacological stimulation of ␣7 nAChRs and inhibition of ␣6␤2 * nAChRs.
Nicotinic receptor composition, function, and expression

Nicotinic receptor diversity
The first studies of synaptic physiology, a necessary prelude to understanding brain function, were conducted at the neuromuscular junction, where the neuronal release of ACh leads to the activation of ion channels and, ultimately, muscle contraction. Although classified as nicotinic, the synaptic receptors of the mammalian neuromuscular junction are only weakly activated by nicotine and are physiologically distinct from the neuronal nAChRs with regard to their subunit composition. This facilitates selective targeting of nAChRs in the brain where nicotine reinforcement takes place. 35 The diverse composition and neuroanatomical location of neuronal nAChRs contributes to their unique roles in addiction, attention, emotion, and other behaviors, making selective targeting of subclasses of nAChRs possible for the treatment of tobacco addiction.
Like nAChRs at the neuromuscular junction, neuronal nAChRs are ligand-gated ion channels made up of five subunits. Consideration of the subunit composition of muscle-type receptors led to the assumption that there were two agonist binding sites in each receptor pentamer, at the interfaces between the ␣ (in current nomenclature, ␣1) subunits and non-␣ subunits. The non-␣ subunits contributing to agonist binding sites were identified as the ␦ and either ␥ or ε subunits at muscle nAChRs. These sites for binding ACh and other agonists are referred to as the orthosteric binding sites to distinguish them from various allosteric sites where other ligands or proteins may bind to regulate the receptors properties in ways that can either increase or decrease the likelihood of channel activation. The muscle ␤ subunit (in current nomenclature, ␤1) does not bind agonist. Subunits filling this fifth position in a pentamer have come to be known as structural or accessory subunits, which do not necessarily participate in binding. Heteromeric neuronal nAChRs contain a combination of ␣ and ␤ subunits, with binding believed to take place at the interface of ␣ and its neighboring subunit. Models of receptor subunit composition based on the muscle receptor have been useful in understanding the functionality of the first nAChR subunit genes cloned from neuronal tissues. Some subunits were identified as ␣ analogs on the basis of the presence of vicinal cysteines in the ligand-binding domain; however, it was unclear how to classify the neuronal non-␣ subunits. The observation that they could only substitute for ␤1 subunits led to the classification of all neuronal non-␣ subunits as ␤ analogs. 36 In total, nine additional ␣-type subunits (␣2-␣10) and three additional ␤ subunits (␤2-␤4) have been cloned from neuronal tissue, although ␣8 has not yet been reported to be expressed in mammals. The model for a heteromeric receptor complex applied well to the first neuronal genes cloned. The ␣2, ␣3, and ␣4 genes formed functional receptors when expressed in Xenopus oocytes with either ␤2 or ␤4, each pair apparently able to form functional ligand-binding domains with distinct properties. 37 Pairwise expression of these subunits, however, results in mixed receptor populations, as either an ␣ or a ␤ can take the accessory subunit position, resulting in receptors with distinct functional 38 and pharmacological properties. 39 Two subunits, ␣5 and ␤3, do not appear to participate in functional agonist binding sites but can co-assemble with other subunits, serving as accessory subunits. 40, 41 Although such accessory subunits do not contribute to the primary agonist binding sites, they nonetheless have important effects on the function and pharmacology of the receptor subunit complexes. 42, 43 The characterization of the heteromeric neuronal nAChR (summarized in Fig. 1 ) also provided insight into early autoradiographic characterization of nicotine binding sites in the brain. 44 The ubiquitous pattern of high-affinity binding of nicotine corresponded to the overlapping expression pattern for ␣4 and ␤2 subunits, 45 which are now known to constitute the main high-affinity nicotine receptors in the rodent brain. ␣4␤2 * receptors (receptors containing two ␣4␤2 agonist binding dimers and a fifth subunit, most often ␣4, ␤2, or ␣5) are the most abundant class of heteromeric nAChR in the It is important to note that stimulation of nAChRs does not typically occur in isolation but en mass. In moving from the unbound resting state to the fully bound resting state, pools of nAChRs will initially show synchronized behavior, with many channels open all at once for a brief period. Subsequent to an initial period, when many channels will be open with high probability, channels will begin to accumulate in the desensitized state and remain there with greatest probability until levels of agonist occupancy are reduced following the diffusion or metabolism of transmitter. rodent brain. 27 A phenylalanine residue present in the ␤2 subunit is thought to contribute to the high affinity of ␤2 * nAChRs. 46 This high-affinity class of nAChRs also includes the ␣-conotoxin MIIsensitive subclass of receptors, ␣6␤2 * and ␣3␤2 * , which may coexpress with the ␣4 subunit. [47] [48] [49] With the exception of the medial habenula and the fasciculus retroflexis, where ␣-conotoxin MII binding is primarily attributed to ␣3␤2 * nAChRs, 32,50-52 and the ventral tegmental area (VTA) and interpeduncular nucleus, where ␣3␤2 * and ␣6␤2 * nAChRs are coexpressed, most ␣-conotoxin MII binding in the brain occurs at the ␣6␤2 * nAChRs. In contrast to ␣4␤2 * nAChRs that do not express ␣3 or ␣6, the ␣-conotoxin MII-sensitive nAChRs have a more restricted expression profile in catecholaminergic nuclei in the brain. 31, 32, 53 Of relevance for their role in tobacco addiction, as will be discussed later in this review, the ␣6␤2 * nAChRs are greatly enriched in VTA DA neurons.
For a number of years, a mystery remained concerning a putative class of nAChRs in the brain that did not bind nicotine or ACh with high affinity, but did bind the snake toxin ␣-bungarotoxin, which had proven useful in isolating the muscle nAChR. Understanding these binding sites came only with the discovery of a second family of nAChR subunits, ␣7-␣10, which could function as homomeric, or sometimes heteromeric, complexes without requiring coassembly with ␤ subunits. 54, 55 The unique properties of these homomeric receptors, in contrast to the ␤2 * nAChRs, are given special consideration in this review.
Nicotinic receptor function
Nicotinic Ach receptors are allosteric proteins that have multiple conformational states, with the equilibria among these states regulated by ligand binding. The simplest models allow for the existence of distinct states, including resting, activated, and desensitized states, as illustrated in Figure 2 . 56, 57 Positioned on neuronal dendrites, soma, and terminals, neuronal nAChRs are expressed widely throughout the nervous system on cells that release diverse neurotransmitters. Since agonist binding results in both activation and desensitization, nAChRs promote nicotine-and ACh-associated modulation of neuronal function, including stimulation or inhibition of neurotransmitter release. 58, 59 In the brain, ACh is released in a relatively diffuse manner, functions primarily as a modulator of neuronal function, and subsequently affects the release of various neurotransmitters, including glutamate, gamma aminobutyric acid (GABA), NE, serotonin, ACh itself, and DA. Binding of endogenous ACh or exogenous agonist compounds (e.g., nicotine) at the orthosteric binding sites results in an increase in the probability of opening of the nAChR ion channel, permits passage of cations across the membrane of the neurons, and leads to depolarization of the cell, which can facilitate neuronal firing. [60] [61] [62] The ligand activity at allosteric binding sites that can positively or negatively modulate the function of agonist-bound nAChRs will be considered further in a later section of this review. The activated state of the receptor is intrinsically unstable and further conformational changes are likely to occur, associated with nonconducting desensitized states. It is generally believed that the receptor activation achieved with cigarette delivery of nicotine, albeit transient, is important for the immediate reinforcing properties of the drug and that this reinforcement is associated with a parallel increase in mesolimbic DA release. After a period of excitation, which varies widely across the heteromeric and homomeric receptor subtypes, the heteromeric nAChRs thermodynamically favor a desensitized state in which the channels are closed with the agonist still bound to the receptor. 63 In this highest affinity state, the desensitized heteromeric nAChRs are typically unavailable for ligand-gated activation; however, evidence suggests that an intermediate level of desensitization can occur where both the ␤2 * nAChRs and the ␣7 nAChRs equilibrate between activated and desensitized states, resulting in low levels of steady-state activation. 64, 65 Following a period of desensitization, upon removal or metabolism of the agonist, the receptors typically revert back to the inactive, unbound state. It is widely accepted that activation of the ␤2 * nAChRs, including ␣4␤2 and ␣6␤2 * nAChRs, is both necessary and sufficient for nicotine self-administration and reward. 3, 5, [8] [9] [10] [11] Recent evidence suggests that a variety of nicotine addiction behaviors, including nicotine reinforcement, are supported by inhibition of diverse nAChR subtypes. 13, [66] [67] [68] Heteromeric α6β2 * nAChRs The ␣6␤2
* nAChRs (including ␣6␤2, ␣3␣6␤2, ␣6␤2␤3, ␣3␣6␤2␤3, ␣4␣6␤2, and ␣4␣6␤2␤3) are members of an ␣-conotoxin MII-sensitive subclass of ␤2
* nAChRs that have a high affinity for nicotine and ACh. Genetically modified mice engineered to be hypersensitive to agonist compounds 11, 69 or in which each of these subunits, alone or in combination, have been deleted 7, 9, 32, 47, 50, 70 have further contributed to our knowledge of the expression and function of these nAChRs. The ␣6 subunit was initially identified by cloning and is most homologous to the ␣3 subunit, 71 perhaps explaining their shared affinity for ␣-conotoxin MII when coupled with ␤2. The development of more refined conotoxins for the study of ␣6
* nAChR subtypes and studies in traditional heterologous systems indicate that ␣6 subunits may also coassemble with ␣3 and ␤4 without a ␤2 subunit in the retina and the dorsal root ganglion. [72] [73] [74] [75] [76] Genetic null mutations of ␣3 and ␣6 subunits in mice show that, with the exception of the interpeduncular nucleus and the VTA, where ␣3␤2 * and ␣3␣6␤2 * nAChRs are coexpressed with ␣6␤2 * nAChRs (minus ␣3), most ␣-conotoxin MII binding is to ␣6 * nAChRs; 50, 52 thus, this ligand selectively binds and antagonizes ␣6␤2 * nAChRs in VTA DA terminal projection areas. ␣6 and ␤3 mRNA are coexpressed in catecholaminergic nuclei, and pull-down assays show that ␣6␤2 * nAChRs have a high incidence of coexpression with ␤3 as an accessory element. 40, 48, 70 A number of studies suggest that ␣4 may also coexpress with ␣6 and ␤2 and that VTA ␣4␣6␤2 * nAChRs are uniquely more sensitive to nicotine than ␤2 * nAChRs that do not assemble with both of these subunits. Functional ex vivo studies suggest that, minus an ␣3 subunit, the full complement of ␣6␤2 * nAChRs promotes DA release at the terminals. [48] [49] [50] Understanding the function of ␣6␤2 * nAChRs presented a special challenge since ␣6 and ␤2 subunits do not readily form receptors in cell lines or Xenopus oocytes. Molecular pharmacology studies using ␣6/␣3 chimeras and molecular concatamers, which clone the precise subunit composition and organization of the nAChRs, confirm that ␣6␤2␤3 and ␣4␣6␤2␤3 nAChRs are permeable to calcium and are bound by compounds, such as varenicline and dihydrobetaerythroidine (DH␤E), that also bind to ␣4␤2 * nAChRs. 19, 64, 77 Although it would appear that the ␣4 subunit contributes largely to this shared affinity, 19, 77 it has proven difficult with pharmacology alone to distinguish the contributions of ␣4␤2 nAChRs, ␣6␤2
* nAChRs, and ␣4␣6␤2 * nAChRs. Ex vivo electrophysiology of VTA DA neurons of wild-type ␣6 and ␣4 subunit knockout mice shows that 300 nM concentrations of nicotine, which preferentially desensitize ␣4␤2 * nAChRs without an ␣6 subunit, result in stimulation of ␣4␣6␤2 nAChRs. 48, [78] [79] [80] These data reveal that mesolimbic ␣4␣6␤2 * nAChRs are uniquely sensitive to activation in response to physiologically relevant concentrations of nicotine that are achieved during smoking, as demonstrated in Figure 3A . In addition, nicotine amplifies the action of endogenously released ACh in modulating DA release via these receptors, 81, 82 perhaps through a different mechanism. Gain-of-function mice created by mutating a Ser residue to Leu in the M2 domain of the ␣6 subunit have further enhanced electrophysiological and neurochemical studies of ␣6 * nAChRs to show that stimulation of ␣6 * nAChRs is sufficient to enhance DA neuron firing in response to nicotine or ACh. 69 Although ␤2
* nAChRs are ubiquitously expressed throughout the brain, ␣-conotoxin MII-binding studies show that ␣6␤2 * nAChRs have a more selective expression profile. Numerous studies have demonstrated functional ␣6 nAChRs in central nervous system (CNS) catecholamine neurons. 83 An accumulation of data suggests that nicotine addiction behavior is regulated in large part by the mesocorticolimbic DA pathway, which projects from the VTA to the nucleus accumbens (NAc), anterior cingulate cortex, hippocampus, and amygdala; hence, it is of relevance to their putative role in the tobacco addiction phenotype that ␣6␤2 * nAChRs are highly enriched in the DA neurons of the VTA. The ␣6␤2 * nAChRs are coexpressed with ␣3␤2 * nAChRs in the VTA but are preferentially expressed on DA terminals in the NAc. Although a combination of ␤2 * nAChRs contribute to nicotine-stimulated DA release in the NAc, [48] [49] [50] cyclic voltammetry studies suggest that ␣6␤2
* nAChRs support 80% of DA release at terminals.
81 ␣6␤2 * nAChRs are much less involved in dorsal striatum DA release 81, 84 but are likely to contribute to motoric behavior at the level of the substantia nigra, where decreases in ␣6␤2 * nAChRs expression are associated with DA Parkinson disease phenotype in humans and animal models. 85, 86 The development of increasingly more selective ␣-conotoxin MII compounds has enabled the study of ␣6 in isolation of ␣3 where these receptors are coexpressed. 52, 87 More recently, the presence of ␣6␤2 * nAChRs has also been reported in presynaptic GABAergic boutons, 88 in noradrenergic terminals in the hippocampus, 89 and on retinal glutamatergic projection neurons and GABAergic soma in the superior colliculus of the visual system.
90
␣6
* nAChRs are located postsynaptically on the cell body, where they regulate cell firing and mediate direct postsynaptic effects. ␣6 * nAChRs are also located presynaptically on nerve terminals, where they serve to modulate the release of neurotransmitters, including DA, 49 NE, 91 and GABA. 92 In the periphery of mammals, the adrenal gland participates in the release of catecholamines, primarily adrenalin, into the bloodstream. In humans, this release is modulated in part by ␣6 * nAChRs, 75 suggesting that ␣6 * nAChRs contribute to systems that regulate arousal.
Homomeric α7 nAChRs ␣7 nAChRs are distinguished from other nAChRs by a number of unique physiological and pharmacological properties, including a high permeability to calcium (PCa:PNa of ࣙ10), and rapid and reversible desensitization. 55 Even under optimized conditions, the maximal probability for any single ␣7 receptor within a large population to participate in a synchronized transient current is two orders of magnitude lower than that of a typical heteromeric receptor. Under optimal steady-state conditions, the probability of any single ␣7 receptor being open is less than one in a million. 93 This low probability of being open, in part, reflects the extreme instability of the open conformation under control conditions, when rarely occurring isolated channel openings are typically less than 100 s in duration. ␣7 nAChRs are expressed in the inderpeduncular nucleus, the NAc shell, and the VTA of the mesolimbic DA pathway, where they regulate nicotine-stimulated DA neuron activity (discussed in greater detail below). 34, 94 The ␣7 subunit is also expressed at high levels in the hippocampus and hypothalamus, 55, 95 and ␣-bungarotoxin binding is enriched in deep layers of the cortex. 44 In addition to brain areas that regulate cognition, attention, and arousal, ␣7 nAChRs have been shown to have functionally important expression in nonneuronal tissues, such as cells of the immune system. 96 Phylogenetic data indicate that the ␣7 gene represents a sort of ancestral nAChR, a protein that may have evolved in organisms that did not rely on fast chemical neurotransmission. This is consistent with the presence of ␣7 in numerous non-neuronal cell types [97] [98] [99] and the fact that ␣7 receptors are not strictly receptors for ACh but respond also to choline, 100,101 the ubiquitous precursor to ACh. This feature suggests that ␣7 nAChRs are adapted to respond following enzymatic breakdown of ACh and suggests a possible mechanism by which ␣7 nAChRs may oppose the activity of the ␤2 * nAChRs. Recent evidence supports a modulatory role for ␣7 nAChRs in the VTA in decreasing ␤2 * nAChR function via stimulation of intracellular signaling cascades that inhibit ␤2 * nAChRs. 94 The functional properties of ␣7 receptors have been studied in Xenopus oocytes, 65 ,102 cultured hippocampal neurons, [102] [103] [104] [105] [106] mammalian cell lines, 93 and native neuronal tissues. 107 One consistent finding is that the kinetic properties of ␣7 receptors cannot be adequately described by the models of heteromeric nAChR discussed above.
For a quiescent population of heteromeric nAChRs in the absence of agonist, the rapid application of a concentration of ACh sufficiently high to saturate the agonist binding sites produces maximal synchronous transient activation. When a similar application of agonist is made to a population of ␣7 receptors, the maximal synchronous transient activation occurs when only a fraction of the agonist binding sites are occupied. 93, 102, [108] [109] [110] This observation suggests that, as with the case of heteromeric receptors, the allosteric effects of binding to just one or two of the five possible binding sites may promote channel opening, but at higher levels of binding, the receptor is most likely to adopt nonconducting conformations, as illustrated in Figure 3C . Recent data suggest that in addition to functioning rather inefficiently as a ligand-gated ion channel, ␣7 nAChRs may also mediate channelindependent signal transduction. 111, 112 However, it is perhaps more likely that ␣7 ion channel activity is essential for modulating reward in the dopamine pathways of the brain, as indicated for the cognitive effects of ␣7 agonists. 113 As will be discussed in more detail, pharmacological compounds that have their action at an allosteric binding site of the ␣7 nAChRs can both promote activation and destabilize desensitization of the ␣7 nAChRs.
Preclinical evidence to support inhibition of ␣6␤2
* and stimulation of ␣7 nAChRs as therapeutic strategies for tobacco cessation
Selective inhibition of α6
* nAChRs impairs nicotine use Since the first null mutation of the ␤2 nAChR subunit demonstrated that ␤2 knockout mice would not self-administer nicotine, 9 it has become widely accepted that activation of the ␤2 * nAChRs supports nicotine reinforcement and reward. It had been presumed that this was due to ␤2 nAChR subunit assembly with ␣4; more recent studies have expanded upon this data to suggest that mesolimbic ␤2 * nAChRs that assemble with an ␣6 and/or ␣4 subunit play a critical role in both the initiation 10 and maintenance of nicotine self-administration. 3, 5 Mice with a null mutation of the ␣4, ␣6, or ␤2 nAChR subunit gene do not acquire nicotine self-administration. Initiation of nicotine self-administration is rescued in these mice, however, with selective neuroanatomical re-expression of each of these subunits in the VTA region, 10 suggesting that ␣4␣6␤2 * nAChRs in DA neurons are critical for initiation of nicotine reinforcement, as depicted in Figure 3 . A combination of pharmacological and genetic studies have identified a class of DA neurons in the VTA that is highly sensitive and persistently activated by nicotine, requiring both the ␣4 and ␣6 subunits. 78 More chronic nicotine self-administration studies reveal that activation of mesolimbic ␣6␤2 * nAChRs in the VTA 5 as well as on DA terminals in the NAc shell 3, 48 are critical for maintenance of nicotine self-administration and nicotine-stimulated DA release. Intra-VTA infusion of DH␤E, an antagonist of ␣4␤2 * and ␣6␤2 * nAChRs, or a selective ␣6␤2 * nAChR antagonist, ␣-conotoxin PIA, blocks systemic nicotine self-administration in well-trained rats, 4,5 but some studies on intra-VTA nicotine selfadministration suggest a dichotomous role for these receptors in the VTA. 82 Selective antagonism of ␣6␤2 * nAChRs in the NAc shell also significantly attenuated the degree to which animals were willing to work for an intravenous nicotine infusion, 3 suggesting that ␣6␤2
* nAChRs are exerting their effects on the terminals of VTA DA receptors as well as on the soma. In this latter study, rats were reinforced on a progressive ratio schedule of reinforcement, which is thought to measure motivation for drug reinforcers. 114 Local delivery of drugs into the brain provides internal experimental control that is not afforded by systemic administration and allows neuroanatomical interpretation of the data, but from a therapeutic perspective, it is important to test whether global inhibition of ␣6␤2 * nAChRs will decrease the reinforcing efficacy of nicotine without having unintended effects on other behaviors. This research has been limited by the fact that the selective ␣6␤2 * nAChR peptide antagonists described above do not cross the blood-brain barrier. Recent development of a putative selective antagonist of ␣6␤2 * nAChRs has revealed that this novel compound, BPiDI, shows similar effects to ␣-conotoxin MII antagonists in reducing nicotine-induced DA overflow in striatal slices. 115 Similar to local infusions of selective ␣6␤2
* nAChR antagonists into the NAc or VTA, subcutaneous injection of BPiDI is effective at reducing nicotine self-administration, suggesting that this compound crosses the blood-brain barrier. 115 Further studies are needed to determine the selectivity of this drug to curbing nicotine use, as systemic administration of BPiDI also inhibited food self-administration. 115 Preclinical studies using ethanol as a primary reinforcer suggest that
␣6␤2
* nAChRs in the VTA may broadly regulate drug reward and the conditioned reinforcing properties of cues associated with drug reinforcers. 116, 117 Given the expression of ␣6␤2 * nAChRs in the visual system and substantia nigra, 50, 53, 90 systemic effects of compounds that reduce ␣6␤2 * nAChR activity should also be assessed for potential visual and motor side effects before advancement to clinical trials. Off-target effects of drugs may be subverted using negative allosteric modulators or partial agonist drugs. Varenicline, which is a partial agonist at ␣6␤2 * nAChRs as well as ␣4␤2 * nAChRs, is purported to have its beneficial effect on smoking cessation through its partial agonist properties at ␤2 * nAChRs. 118, 119 Varenicline's full agonist properties at ␣7 nAChRs 20 may also prove relevant for its efficacy in smoking cessation, as is discussed below. Incomplete inhibition of ␤2 * nAChRs with a partial agonist rather than a full antagonist is intended to circumvent precipitation of withdrawal while blunting nicotine reinforcement. Studies in mice, however, show that global CNS delivery of a selective ␣6␤2 * nAChR antagonist peptide reduces affective withdrawal and has no effect on somatic withdrawal behavior in mice. 6 Together, these behavioral, pharmacological, and genetic data suggest that inhibition of ␣6␤2 * nAChRs may be an effective strategy to promote tobacco cessation in human subjects, but there is a need for further development and study of selective ␣6␤2 * nAChR antagonists, partial agonists, and negative allosteric modulators that cross the blood-brain barrier.
Selective activation of α7
* nAChRs decreases motivation for nicotine use Compared to ␤2 * nAChRs, identifying contributions of ␣7 nAChRs to nicotine reinforcement has proved to be more difficult. Early studies in ␣7 null mutant mice suggested that ␣7 nAChRs are not critical for nicotine discrimination 120 and that a lack of ␣7 nAChRs had little effect on nicotine place conditioning or initiation of oral nicotine self-administration. 10, 12, 30 Studies testing nicotine self-administration in rats have returned mixed results using methyllycaconitine (MLA), 121, 122 an ␣7 nAChR antagonist with poor penetration of the blood-brain barrier. Moreover, since MLA significantly blocks ␣-conotoxin MII-sensitive release of DA and binding, it is not clear if reductions of intravenous nicotine self-administration observed following MLA exposure result from ␣7 nAChR antagonism 122 or blockade of ␣6␤2 * nAChRs. 123 Using a highly selective ␣7 nAChR antagonist, ArIB, local inhibition of ␣7 nAChRs in the anterior cingulate cortex or the NAc shell results in a threefold increase in rat responding for nicotine under progressive ratio schedules. 22 Given that the low doses of nicotine achieved under this stringent schedule of reinforcement are not likely to result in a net stimulation of ␣7 nAChRs, this increased motivation for nicotine is likely the result of blockade of endogenous ACh or choline signal at these receptors rather than a blockade of nicotine signal. It has been reported that knockout mice lacking ␣7 nAChRs show reductions in oral preference for nicotine compared to their wild-type counterparts, 30 though it is not clear from the two-bottle choice paradigm if the knockout mice "like" nicotine less or if they are titrating their doses because they are more sensitive to nicotine. The latter hypothesis is supported by recent data showing that nicotine-conditioned place preference is shifted to the left in ␣7 nAChR knockout mice at exceptionally low nicotine doses. 24 This preclinical evidence in rodents may provide some insight into the heavy smoking behavior of individuals with schizophrenia, [124] [125] [126] [127] [128] [129] [130] [131] who in postmortem studies show a 50% decrease in expression of ␣7 nAChRs. [132] [133] [134] [135] [136] [137] [138] [139] Evidence from a preclinical animal model of smoking cessation efficacy shows that stimulation of ␣7 nAChRs decreases nicotine self-administration. In contrast to antagonist studies, local infusion of a highly selective ␣7 nAChR agonist into the NAc shell, like antagonism of ␣6␤2 * nAChRs, results in significant decreases in motivation to self-administer nicotine, as measured by reduced responding under progressive ratio schedules. 22 In support of rat self-administration, which suggests that stimulation of ␣7 nAChRs reduces nicotine reinforcement, administration of a selective ␣7 nAChR agonist blocked nicotine reward behavior in the place-conditioning paradigm and ␣7 gainof-function mice failed to demonstrate nicotine reward in this paradigm at a wide range of doses. 24 It would appear from these studies that, rather than its activation being required for nicotine reinforcement, stimulation of ␣7 nAChRs modulates self-administration behavior. Selective removal of the ␣7 nAChR function removes this modulation, leaving the ␣6␤2 * and other heteromeric ␤2 * nAChRs unopposed, as depicted in the model shown in Figure 3 22,94,140 (but see Ref. 141 ). Unlike ␤2 subunit null mutant mice, who fail to show nicotinestimulated DA release, 9 nicotine-stimulated DA release is significantly elevated in the NAc of ␣7 nAChR knockout mice. 141 Whether ␣7 nAChRs directly or indirectly decrease ␣6␤2 * nAChR function in the NAc shell or if the two subtypes of nAChRs exert their primary effects via a common downstream effector is unclear. Within the VTA, however, recent studies indicate that inhibition of ␣7 nAChRs on DA neurons leads to elevated ␤2 * nAChR activity on these neurons and that activation of ␣7 nAChRs, via changes in peroxisome proliferator-activated receptors type-␣ signaling, leads to subsequent decreases in ␤2 * nAChR function. 94 Independent of mechanism, together these findings support stimulation of ␣7 nAChRs as a novel means by which to curb tobacco use. Further studies are needed to assess the effects of systemic administration of compounds that stimulate ␣7 nAChRs on a nicotine addiction phenotype. Due to potential benefits for cognition and memory, drug development on this front has received more focus than compounds targeting ␣6␤2 * nAChRs. A number of selective agonists and positive allosteric modulators of ␣7 nAChRs are being developed for other uses and are already in clinical trials. 142 Preclinical and clinical studies of these ligands may reveal a novel therapeutic for smoking cessation.
Pharmacological tools for inhibition of ␣6␤2
* and activation of ␣7 nAChRs: implications for drug development Targeting α6β2 * nAChRs and α7 nAChRs for tobacco cessation With the relatively rapid delivery of nicotine achieved with cigarettes, a phase of high-affinity receptor activation is typically followed by the onset of equilibrium desensitization of nAChRs. As detailed above, activation of mesolimbic ␣6␤2 * nAChRs occurs at lower concentrations than for ␣4␤2 * nAChRs that do not express ␣6, 78 and several studies suggest that populations of ␣6␤2 * nAChRs also show a slower decay rate, suggesting that ␣6␤2 * nAChRs may have longer periods of net activation than other subclasses of nAChRs. 77, 78, 143, 144 An accumulation of preclinical data showing that inhibition of ␣6␤2 * nAChRs reduces nicotine-stimulated DA release, nicotine reward, and intravenous nicotine self-administration 3,5,9,10,47,48,115 supports inhibition of ␣6␤2 * nAChRs as a strategy for tobacco cessation. In contrast, the ␣7 nAChRs are less likely than heteromeric nAChRs to either be activated or stabilized in desensitized states by levels of nicotine achieved in the brains of smokers, but these receptors are responsive to both ACh and its metabolic precursor and breakdown product choline. 100, 101 Rather than their activation being required to support nicotine self-administration, ␣7 nAChRs appear to act as modulators of nicotine reinforcement that work in opposition to the ␣6␤2 * and ␣4␤2 * nAChRs. In contrast to findings with ␣6␤2 * nAChRs, selective genetic and pharmacological inhibition of the ␣7 nAChRs increases motivation to intravenously self-administer nicotine and results in elevated nicotine-stimulated DA release. 22, 141 On the other hand, as selective agonism of accumbens ␣7 nAChRs decreases motivation for nicotine self-administration, the data support stimulation of ␣7 nAChRs as a strategy to promote tobacco cessation (Fig. 4) . 22 Route of administration Consideration should be given to the route of administration when developing therapeutics for tobacco cessation. Therapeutics in their most common forms are slow delivery products. When a potentially activating molecule such as nicotine is delivered slowly, as with systemic administration via a patch or pill, there is likely to be relatively little synchronized receptor activation, and, instead, receptors equilibrate among multiple conformational states. 145, 146 This equilibrium predominantly favors desensitization and therefore also blunts receptormediated responses to endogenous cholinergic stimuli. This may explain why most forms of nicotine replacement are effective in a small minority of smokers who are motivated to quit. Once deemed safe, faster delivery platforms, such as e-cigarettes, could provide an effective delivery system for compounds intended to stimulate nAChRs. Route of administration should not be a concern with delivery of antagonist and partial agonist drugs intended to inhibit receptor activity, as would be the strategy with ␣6␤2 * nAChRs, but the typical oral and cutaneous routes of drug administration could preclude sufficient delivery of an agonist that could selectively stimulate ␣7 nAChRs. As described briefly above and in detail elsewhere, 110 however, the concentration-dependent form of ␣7 nAChR desensitization renders the ␣7 nAChRs uniquely sensitive to a class of highly selective positive allosteric modulators (PAMs), which can destabilize one or more desensitized states and thereby greatly increase the probability of channel opening. Also, as noted above, the desensitized states of ␣7 receptors can be further distinguished from those of heteromeric nAChRs because they do not show significantly increased affinity for agonists compared to the resting state of the receptor. As a consequence, while the prolonged presence of a low concentration of ACh, or a drug such as nicotine, will induce high levels of heteromeric receptor desensitization, ␣7 receptors will be largely unaffected and remain responsive to fluctuating stimuli generated from endogenous ACh signals. ␣7 nAChR PAMs may increase the sensitivity, efficacy, and duration of these ACh signals.
Ligands that inhibit α6β2 * nAChRs There are two major challenges in designing therapeutics that selectively antagonize ␣6␤2 * nAChRs. The first has been to develop drugs that bind the ␣6 subunit without having appreciable affinity for ␣3 * and ␣4 * nAChRs in the absence of the ␣6 subunit. The second has been to develop compounds with high selectivity for ␣6␤2 * nAChRs that cross the blood-brain barrier. The first of these challenges can be achieved by screening molecules against libraries of ␣6/␣4 or ␣6/␣3 chimeras in functional assays. This strategy has led to the development of peptide compounds with significant sensitivity for the ␣6 subunit over ␣3 * nAChRs, which are prevalent in the autonomic ganglia and over ␣4 * nAChRs, which are ubiquitously expressed throughout the brain. 87, [147] [148] [149] [150] Recent studies utilized ␣-conotoxin BuIA, a compound with known binding selectivity for ␤2 over ␤4 and a 50,000-fold higher potency for ␣6␤2 * compared to ␣4␤2 * nAChRs to determine the sites of the ␣ subunit interface that confer binding affinity and potency. These studies revealed that replacing residues 59-207 of the ␣4 subunit with the corresponding residues from ␣6 results in more than a 7000-fold increase in IC 50 efficacy compared to its action at ␣4, with critical sites present on the Cloop between residues 184 and 207 of ␣6. 148 Cone snail toxins, which bind to vertebrate and mammalian ␣6 * nAChRs, have provided a valuable, naturally occurring template from which to develop compounds that selectively target ␣6␤2 * nAChRs; these large molecule peptides, however, do not readily penetrate the blood-brain barrier. Adapting the size and lipophilicity of these peptides to encourage passive diffusion is impractical, and the compound may still have difficulty accessing the target receptors. Recent developments suggest that the saturable transport systems may prove to be a more efficient means of providing drug delivery to the CNS. 151 The addition of structures intended to shepherd the ␣6␤2 * nAChR antagonists across transporters in the endothelial layer or choroid plexis could increase the bioavailability of ␣6␤2
* nAChR ligands, but should be carefully screened to assure that they do not alter compound affinity, selectivity, or efficacy. To date, there are no selective ␣6␤2 * nAChR compounds in clinical trials, but the field is rife with scientific tools to support their development.
Partial agonists and negative allosteric modulators (NAMs) provide additional strategies to promote inhibition of ␣6␤2 * nAChRs. Although much more selective in their neuroanatomical expression than ␣4␤2 * nAChRs, a prevalence of ␣6␤2 * nAChRs in the nigrostriatal pathway and the visual system may call for therapeutic approaches that inhibit, rather than block, neurotransmission at these receptors. Negative allosteric modulation of the ␣6␤2 * nAChRs could prove sufficient to reduce activity of mesolimbic ␣6␤2
* nAChRs without adversely affecting the function of these receptors in the visual and motor systems. The pharmacology of the partial agonist varenicline has a significant effect at ␣6␤2 * nAChRs. 77, 152 Recent development of novel bispidine ␤2 * nAChR partial agonist compounds with a lower affinity than varenicline for ganglionic ␣3␤4 nAChRs may also promote smoking cessation while reducing side effects, but these drugs need to be tested for their affinity to ␣6␤2 * nAChRs and for their capability to reduce nicotine selfadministration. 153 As we have come to understand that ␣6␤2 * nAChRs are a critical subclass of ␤2 * nAChRs that support nicotine reinforcement, 3, 5, 10 a more selective ␣6␤2 * nAChR partial agonist may prove to have greater efficacy or reduced side effects in smokers. Since varenicline is a full agonist at ␣7 nAChRs, albeit with lower affinity than for its action at ␤2 * nAChRs, 20 it would be of further interest to discover if there is synergy in a combined therapeutic approach that supports inhibition of ␣6␤2 * nAChRs and stimulation of ␣7 nAChRs.
Ligands that stimulate α7 nAChRs Selective stimulation of ␣7 nAChRs is an innovative strategy for smoking cessation treatment. A number of highly selective ␣7 nAChR agonists and PAMs of diverse structure have been developed in recent years. 142 Full and partial ␣7 nAChR agonist drugs mimic the effects of cholinergic and nicotine stimulation, but unlike global nAChR stimulation, preclinical studies show that selective agonism of ␣7 nAChRs reduces motivation for nicotine use. 22 Agonist drugs lead to rapid desensitization of nAChRs, but as mentioned above, the desensitized state of ␣7 nAChRs is not as stable as that of the high-affinity heteromeric nAChRs.
Another means of achieving stimulation of ␣7 nAChRs is via positive allosteric modulation of these receptors. As opposed to a full agonist, which mimics the effects of ACh, choline, and nicotine to activate the ␣7 nAChRs, a nAChR PAM exerts no nAChR activity on its own, but enhances the efficacy of a full agonist via binding at an alternate allosteric site. 110, 154 Type I PAMs may lower the activation threshold of nAChRs to agonist ligands. Type II PAMs additionally increase nAChR responsiveness to agonist ligands, enhance channel current amplitudes, and slow the decay of channel current activity, suggesting that type II PAMs destabilize nAChR desensitization to increase equilibrium current (Fig. 4C) . 155 Although PAMs that have intrinsic allosteric agonist activity have been described, [155] [156] [157] a true ␣7 nAChR PAM does not activate ␣7 nAChRs on its own, but by binding to an allosteric site (different from the orthosteric nicotine/ACh binding site) selectively enhances nicotine and ACh activity at the ␣7 nAChRs. Hence, administration of PAMs might be expected to decrease motivation for tobacco when individuals are smoking cigarettes or could increase the efficacy of nicotine replacement therapies. Because they have no effect on their own, nAChR PAMs may be less likely than agonist compounds to result in undesirable side effects, but careful screening of these compounds is warranted to ensure that exaggerated receptor stimulation does not cause toxicity, 110, 158 particularly if used in combination with nicotinic agonists. In individuals who have reduced expression of ␣7 nAChRs, such as those with a schizophrenia diagnosis, in vitro ␣7 nAChR expression studies using the truncated, dominant-negative ␣7 duplicate gene suggest that treatment with a type II ␣7 PAM may promote stimulation of these receptors. 159 Both ␣7 nAChR full agonists and ␣7 PAM dosing may need to be adjusted for these individuals, although preclinical studies suggest that PAMs may be less likely than a full agonist to lead to changes in ␣7 nAChRs that could affect dosing after repeated exposure. 160 A number of selective ␣7 nAChR agonists and PAMs have been developed for treatment of cognitive and attention deficits that are evident with CNS disorders, many of which have advanced to clinical trials. 142, 161 With development of clinical trials on tobacco cessation, there is promise that some of these compounds may be repurposed or prescribed off-label to help individuals quit smoking.
Summary
Smoking continues to be a major public health concern. Although existing therapeutics for smoking cessation have attained some success in assisting smokers to quit, a number of individuals have been unresponsive or intolerant to existing treatments. As individuals have a diversity of reasons for smoking, they may also benefit from different cessation strategies for quitting. 162 An accumulation of recent studies identified the heteromeric ␣6␤2 * and homomeric ␣7 nAChRs as promising novel therapeutic targets to promote tobacco abstinence. A combination of electrophysiological, pharmacological, and genetic studies have begun to suggest that the efficacy of drugs that inhibit the ␣4␤2 * nAChRs may indeed be targeting ␣4␣6␤2 * nAChRs. Given their more selective neuroanatomical distribution, drugs that more selectively inhibit ␣6␤2 * nAChR function could achieve therapeutic success with fewer side effects. The broad assumption that activation of nAChRs promotes nicotine reward and reinforcement resulted in the conclusion from early studies in ␣7 nAChR knockout mice that these low-affinity receptors were not critical for nicotine addiction. An accumulation of recent data has begun to identify that, unlike ␤2 * nAChRs, an inverse relationship exists between ␣7 nAChR function and nicotine reinforcement and reward. Reductions in ␣7 nAChR function achieved by genetic or pharmacological manipulation promotes a nicotine addiction phenotype, whereas selective stimulation of ␣7 nAChRs reduces nicotine reward and motivation to self-administer nicotine.
Together, these studies identify novel classes of nAChRs and unique strategies for treatment of tobacco dependence.
